As a scientist, innovator, and CEO of CytoSite BioPharma, Dr. Ben Larimer has reshaped how we think about imaging immune response in cancer. His work on Granzyme B PET imaging is unlocking unprecedented insights into whether—and where—immunotherapies are working inside the body.
In this episode of Fractals, Ben joins host Colin Miller to discuss:
- The origins of Granzyme B imaging and what makes it a uniquely powerful imaging agent.
- How CytoSite’s imaging agent revealed success in preclinical models—and sparked a new clinical path forward.
- The balance between scientific innovation and real-world biotech execution.
- Why PET imaging’s future depends on AI, cost reduction, and deeper diagnostic precision.
Tune into Fractals: Life Science Conversations wherever you get your podcasts—and contact Bracken to learn how we help imaging agents move from molecule to market.
Click here to read the transcript version of this episode.
